Glaucoma Surgery Devices Market Size, Share and Trends 2024 to 2034

Glaucoma Surgery Devices Market Size and Forecast 2024 to 2034

The global glaucoma surgery devices market size is worth around USD 1.78 billion in 2024 and is anticipated to reach around USD 2.79 billion by 2034, growing at a CAGR of 4.62% over the forecast period 2024 to 2034. The glaucoma surgery devices market is experiencing growth due to factors like increasing prevalence, rising geriatric populations, advancement in technology, and rising awareness about glaucoma.

Glaucoma Surgery Devices Market Key Takeaways

• North America dominated the glaucoma surgery devices market with the largest market share of 37% in 2023.
• Asia Pacific is anticipated to grow at a fastest CAGR of 5.26% during the forecast period.
• By product, the traditional surgery devices segment held the largest share of the market in 2023.
• By product, the diamond knives segment is expected to grow at a CAGR of 5.44% during the forecast period.
• By surgery method, the traditional glaucoma surgery segment contributed more than 37% in 2023.
• By surgery method, the minimally invasive glaucoma surgery segment is projected to grow at a significant CAGR of 5.45% during the forecast period.
• By end-use, the hospital segment generated the largest market share of 38% in 2023.
• By end-use, the ophthalmic clinics segment is expected to expand at a notable CAGR of 4.83% during the projected period.

U.S. Glaucoma Surgery Devices Market Size and Growth 2024 to 2034

The U.S. glaucoma surgery devices market size was valued at USD 440 million in 2023 and is expected to be worth around USD 740 million by 2034, rising a CAGR of 4.83% from 2024 to 2034.

North America held the largest share of the glaucoma surgery devices market in 2023 and is expected to sustain its position throughout the forecast period. North America has been the leading region in the market, driven by high awareness of the disease, advanced healthcare infrastructure, and substantial investments in research and development. The American Glaucoma Society (AGS) is a leading organization focused on enhancing the lives of individuals with glaucoma and those at risk by advancing education, research, healthcare access, and advocacy.

• January was National Glaucoma Awareness Month. Glaucoma, a leading cause of vision loss and blindness in the U.S., involves elevated eye pressure damaging the optic nerve. Open-angle glaucoma was the most common type in the country. The CDC reported that 50% of people with glaucoma were unaware of their condition due to a lack of early symptoms.
• The European Glaucoma Society (EGS) has committed substantial efforts to enhance education, training, and testing knowledge in glaucoma.

Asia Pacific is anticipated to witness the fastest growth in the glaucoma surgery devices market during the forecast period. The increasing prevalence of glaucoma, driven by aging populations and lifestyle changes, is increasing the demand for advanced diagnostic and treatment technologies. The expanding healthcare infrastructure and growing investments in ophthalmic research and development contribute to the market expansion. Countries like India, China, and Japan are particularly significant in this growth trend.

• Asia Pacific Congress 2024 will unite clinicians, scientists, students, and other health practitioners in ophthalmology to collaborate and share the latest research and innovation in glaucoma care.
• The Asia Pacific Glaucoma Society (APGS) organized an event aimed at enhancing communication among glaucoma specialists, fostering collaborative research, and updating professionals on advancements in diagnosis and management.
• The National Programme for Control of Blindness & Visual Impairment in the Ministry of Health & Family Welfare reported that glaucoma was one of the leading causes of blindness, accounting for 5.8% of the approximately 12 million cases of blindness in India.

Market Overview

Glaucoma is a chronic, progressive ocular condition that affects the optic nerve and can lead to irreversible vision loss. It is often referred to as the ‘silent thief of sight’ because it slowly damages the optic nerve before causing noticeable central vision loss. The device is used to treat mild to moderate glaucoma and is approved for implantation during phacoemulsification. These devices include those designed to enhance outflow as well as sustained-release drug delivery systems and extraocular devices that aim to reduce glaucomatous progression through the novel method. The glaucoma surgery devices market is expanding due to several key factors. 

Impact of AI on the Glaucoma Devices Market

The integration of artificial intelligence in the glaucoma surgery devices market is rapidly transforming the fields. AI technology enhances the capabilities of glaucoma devices by improving diagnostic accuracy and reducing the need for manual intervention. Artificial intelligence can significantly reduce the need for manual labor and improve the efficiency of classified treatment systems, enabling earlier diagnosis and treatment of more patients.  Notable success in both diagnostic and prognostic aspects. An ideal AI system for glaucoma should comprehensively assess all relevant parameters, including intraocular pressure, disc morphology, gonioscopy, visual fields, and OCT.

• In October 2023, a hospital in Chennai launched a project to use AI for screening both glaucoma and diabetic retinopathy.
• In March 2023, artificial intelligence technology was introduced to improve efficiency and enhance chronic disease management in Shanghai grassroots-level glaucoma screening, as reported by local health authorities during World Glaucoma Week. 

Glaucoma Surgery Devices Market Growth Factors

• Advances in technology and the introduction of innovative diagnostic and treatment options are also fueling market expansion.
• Multiple countries are witnessing effective government policies for diabetes associated cases, such initiative along with improving healthcare infrastructure is observed to promote the market’s expansion. 
• The growing prevalence of age-related eye disorders, including glaucoma, underscores the need for improved healthcare solutions and drives market growth.

Market Scope

Market Dynamics

Drivers

Increasing prevalence of glaucoma

The rising prevalence of eye disorders, particularly glaucoma, is a growing concern in the glaucoma surgery devices market. Glaucoma refers to a group of progressive optic neuropathies that involve the degeneration of retinal ganglion cells and the retinal nerve fiber layer, leading to changes in the optic nerve head. It is a leading cause of irreversible vision loss globally. Although advances in imaging and visual field testing have improved early diagnosis and treatment, many patients remain undiagnosed until the disease has significantly progressed. This delay can result in irreversible vision loss and diminished quality of life.

• According to the World Glaucoma Association, glaucoma was the most common cause of irreversible blindness, with an estimated 79.6 million individuals affected in 2020. This number was projected to rise to 111.8 million by 2040.

Increasing geriatric population

The increasing prevalence of glaucoma, particularly among the geriatric population, is a major factor driving the glaucoma surgery devices market, as this age group is at a significantly higher risk for the disease. Adults over 60 are six times more likely to develop glaucoma, especially if a parent or sibling has the condition. Additionally, certain groups, such as African Americans and Hispanic Americans, are disproportionately affected and face increased risk as they age. Age significantly influences the impact of intraocular pressure on glaucomatous damage to the retinal nerve fiber layer, with older patients often experiencing more rapid progression. 

The Global Burden of Diseases, Injuries, and Risk Factors Study reported that the age-standardized prevalence of glaucoma was approximately 3-5% in the population aged 40 years and older worldwide. This figure was expected to rise to 112 million people by 2040 due to the rapid increase in global population aging.

• In March 2022, The Glaucoma Research Foundation article estimated that in 2010, 8.4 million individuals worldwide were blind from primary open glaucoma. By 2040, it was projected that this number would increase to 22 million people globally who would be blind from glaucoma.

Restraint

The economic burden associated with glaucoma

The significant economic burden associated with glaucoma, particularly as the disease progresses, presents a restraint for the glaucoma surgery devices market. With an estimated 3% of the global population over 40 years affected by glaucoma, many of them remain undiagnosed, and the overall costs associated with advanced stages of the disease can be substantial. As glaucoma progresses, direct medical costs increase, impacting healthcare budgets and patient finances. This economic strain can limit access to advanced glaucoma devices, especially for patients in lower income brackets or regions with less robust healthcare systems. Furthermore, the need for early diagnosis and ongoing treatment adds to the financial burden, potentially constraining market growth for new and innovative glaucoma surgical solutions.

Opportunity

Rising awareness

Rising awareness about glaucoma presents a significant opportunity for the glaucoma surgery devices market. Increased public understanding of the importance of regular eye check-ups, knowledge of family medical history, and adopting healthy lifestyles can lead to earlier detection and intervention. As more individuals become aware of glaucoma’s risks and the necessity for timely treatment, there is a growing demand for advanced glaucoma devices. Early detection and proactive management can drive the market. Enhanced awareness also supports greater adoption of new technologies and processes, ultimately improving patient outcomes and expanding market potential.

• World Glaucoma Week (10-16 March 2024), organized by the World Glaucoma Association (WGA), aims to raise global awareness about glaucoma. It encourages patients, eye-care providers, health officials, and the public to participate in activities that promote regular eye and optic nerve checks for early detection of glaucoma and sight preservation. 

Product Insights

The traditional surgery devices segment held the largest share of the glaucoma surgery devices market in 2023. The traditional surgery devices market is dominated by traditional surgery methods, which have widespread applications. The increase in success rate for glaucoma surgery and the lower treatment costs of traditional glaucoma surgery contribute to its dominance. In underdeveloped economies, conventional glaucoma surgery is preferred as the first-line treatment due to its affordability compared to other segments.

The diamond knives segment is expected to grow significantly in the glaucoma surgery devices market during the forecast period. Diamond knives offer significant advantages over traditional blades in surgical techniques. Scanning electron microscopy has demonstrated that incisions made with diamond knives cause minimal corneal epithelium and stroma disruption, promoting better healing and less postoperative discomfort. Many surgeons prefer diamond knives because they often result in improved surgical outcomes and fast patient recovery times.

• In June 2024, MicroSurgical Technology introduced a diamond knife subscription to reduce waste and lower the carbon footprint associated with cataract surgery.

Surgery Method Insights

The traditional glaucoma surgery segment is expected to dominate the glaucoma surgery devices market in 2023. Its long-standing efficacy and widespread use have driven the market growth. Trabeculectomy, a key procedure in this segment, has been the gold standard for managing advanced glaucoma or cases unresponsive to medical or laser treatment. Despite the emergence of newer techniques, such as the Ex-PRESS glaucoma shunt, which offers a less invasive option and often achieves rapid pressure stabilization, traditional surgery continues to dominate the market due to its extensive history of successful outcomes.

The minimally invasive glaucoma surgery segment is observed to grow at a significant rate in the glaucoma surgery devices market during the forecast period. MIGS techniques, such as Hydrus stent, iStent, and XEN implant, offer rapid visual recovery, high safety, and minimal tissue trauma, making them appealing to both patients and surgeons. MIGS represents a promising, less invasive alternative in glaucoma management with evolving long-term results.

• In January 2023, Palmetto GBA collaborated with CGS Administrators, National Government Services, Noridian Healthcare Solutions, and WPS Government Health Administrators to host a Multi-Jurisdictional Contractor Advisory Committee meeting. Discussions focused on Micro-Invasive Glaucoma Surgery (MIGS).

End-use Insights

The hospital segment led the global glaucoma surgery devices market in 2023. This leadership is largely attributed to the comprehensive care provided in hospital settings, where complex procedures such as glaucoma drainage implant surgeries are performed. The specialized resources, advanced technology, and multidisciplinary teams available in hospitals contribute to their prominence in the glaucoma surgery market.

The ophthalmic clinics segment is expected to witness the fastest growth in the glaucoma surgery devices market during the projected period. This growth is driven by the increasing demand for specialized, accessible, and cost-effective glaucoma treatment. Ophthalmic clinics offer focused expertise in managing glaucoma, including advanced minimally invasive procedures and regular follow-up care.

Glaucoma Surgery Devices Market Companies

• Alcon, Inc.
• Glaukos Corporation
• Johnson & Johnson Vision
• AbbVie Inc. (Allergan Plc.)
• ASICO, LLC
• Carl Zeiss Meditec AG
• Katalyst Surgical
• Lumenis Lt.
• Ziemer Ophthalmic Systems AG
• Iridex Corporation.
• Altomed

Recent Developments

• In July 2024, Alcon acquired Belkin Vision, gaining access to new laser treatment for glaucoma. Alcon planned to introduce this technology to the U.S. market.
• In February 2024, Glaukos launched the iDose TR (travoprost intracameral implant) to reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma. 
• In August 2023, Nova Eye Medical reported strong sales following the U.S. launch of its iTrack Advance glaucoma surgical device. The iTrack Advance, a consumable device with an illuminated fiber optic tip, aimed to improve the efficacy of canaloplasty surgery in treating glaucoma.
• In December 2023, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Eagle device, a glaucoma laser.
• In April 2023, Bausch + Lomb Announced the U.S. Launch of the StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic System. These products provided eye surgeons with new options for dual-action protection during cataract surgery.
• In April 2023, the FDA cleared Nova Eye Medical iTrack Advance for the U.S. launch. These canaloplasty devices were designed for canal-based glaucoma surgery
• In July 2022, Bausch + Lomb and Sanoculis entered into strategic agreements aimed at addressing unmet needs in glaucoma. 

Segments Covered in the Report

By Product 

• Glaucoma drainage device
  • Valves
  • Glaucoma drainage implant
  • Glaucoma tube shunts
  • Stents
• Traditional Surgery Devices
  • Scalpel
  • Forceps
  • Ophthalmic scissors
  • Punch
  • Sutures
  • Surgical drapes
  • Microcatheter
  • Others
• Diamond knives
  • Laser systems
  • Others

By Surgery Method 

• Traditional Glaucoma Surgery
  • Trabeculectomy
  • Tube Shunt Surgery
• Minimal Invasive Glaucoma Surgery
  • Trabecular Meshwork Bypass
  • Suprachoroidal Space Implants
  • Subconjunctival Space Implants
  • Schlemm’s Canal Implants
  • Gonioscopy-assisted Transluminal Trabeculectomy
  • Endocyclophotocoagulation
• Laser Surgery
  • Trabeculoplasty
  • Iridotomy
  • Cyclophotocoagulation

By End-user

• Hospitals
• Ophthalmic clinics
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa